{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:52:14Z","timestamp":1740135134779,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the national key research and development program of china","award":["2018YFE0204500"],"award-info":[{"award-number":["2018YFE0204500"]}]},{"name":"Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund","award":["znpy2019064"],"award-info":[{"award-number":["znpy2019064"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81702273"],"award-info":[{"award-number":["No. 81702273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"science and technology key project of guangdong province: study on the source and epidemiology of covid-19","award":["2020B111107001"],"award-info":[{"award-number":["2020B111107001"]}]},{"name":"scientific research project of covid-19 epidemic prevention and control in guangdong universities","award":["No.2020KZDZX1087"],"award-info":[{"award-number":["No.2020KZDZX1087"]}]},{"name":"key project for anti-2019 novel coronavirus pneumonia from the national key research and development program of china","award":["No. 2020YFC0845500"],"award-info":[{"award-number":["No. 2020YFC0845500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Serosurveillance is crucial in estimating the range of SARS-CoV-2 infections, predicting the possibility of another wave, and deciding on a vaccination strategy. To understand the herd immunity after the COVID-19 pandemic, the seroprevalence was measured in 3062 individuals with or without COVID-19 from the clinic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The levels of SARS-CoV-2 antibody IgM and IgG were measured by the immuno-colloidal gold method. A fusion fragment of nucleocapsid and spike protein was detected by a qualitative test kit with sensitivity (89%) and specificity (98%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The seroprevalence rate for IgM and IgG in all outpatients was 2.81% and 7.51%, respectively. The sex-related prevalence rate of IgG was significantly higher (P\u2009&lt;\u20090.05) in women than men. The highest positive rate of IgM was observed in individuals\u2009&lt;\u200920\u00a0years of age (3.57%), while the highest seroprevalence for IgG was observed in persons\u2009&gt;\u200960\u00a0years of age (8.61%). Positive rates of IgM and IgG in the convalescent patients were 31.82% and 77.27%, respectively, which was significantly higher than individuals with suspected syndromes or individuals without any clinical signs (P\u2009&lt;\u20090.01). Seroprevalence for IgG in medical staff was markedly higher than those in residents. No significant difference of seroprevalence was found among patients with different comorbidities (P\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The low positive rate of the SARS-CoV-2 IgM and nucleic acid (NA) test indicated that the SARS-CoV-2 outbreak is subsiding after 3\u00a0months, and the possibility of reintroduction of the virus from an unidentified natural reservoir is low. Seroprevalence provides information for humoral immunity and vaccine in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-07010-w","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T10:08:03Z","timestamp":1641290883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown"],"prefix":"10.1186","volume":"22","author":[{"given":"Yueting","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bokun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangming","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-0595","authenticated-orcid":false,"given":"Xiaoyang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yirong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"5","key":"7010_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533\u20134.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"7010_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-2600(20)30527-0","volume":"9","author":"L Piroth","year":"2021","unstructured":"Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9(3):251\u20139.","journal-title":"Lancet Respir Med"},{"key":"7010_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.1585.","journal-title":"JAMA"},{"issue":"11","key":"7010_CR4","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/jama.2020.1623","volume":"323","author":"D Chang","year":"2020","unstructured":"Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020;323(11):1092\u20133.","journal-title":"JAMA"},{"issue":"3","key":"7010_CR5","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"CC Lai","year":"2020","unstructured":"Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.","journal-title":"Int J Antimicrob Agents"},{"key":"7010_CR6","doi-asserted-by":"publisher","first-page":"101567","DOI":"10.1016\/j.tmaid.2020.101567","volume":"33","author":"C Biscayart","year":"2020","unstructured":"Biscayart C, Angeleri P, Lloveras S, Chaves T, Schlagenhauf P, Rodriguez-Morales AJ. The next big threat to global health? 2019 novel coronavirus (2019-nCoV): what advice can we give to travellers?\u2014Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI). Travel Med Infect Dis. 2020;33:101567.","journal-title":"Travel Med Infect Dis"},{"key":"7010_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijid.2020.01.050","volume":"92","author":"S Zhao","year":"2020","unstructured":"Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214\u20137.","journal-title":"Int J Infect Dis"},{"issue":"10225","key":"7010_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(20)30260-9","volume":"395","author":"JT Wu","year":"2020","unstructured":"Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689\u201397.","journal-title":"Lancet"},{"issue":"10223","key":"7010_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497\u2013506.","journal-title":"Lancet (London, England)"},{"issue":"9366","key":"7010_CR10","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","volume":"361","author":"JS Peiris","year":"2003","unstructured":"Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet (London, England). 2003;361(9366):1319\u201325.","journal-title":"Lancet (London, England)"},{"issue":"3","key":"7010_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1128\/jvi.67.3.1185-1194.1993","volume":"67","author":"C Daniel","year":"1993","unstructured":"Daniel C, Anderson R, Buchmeier MJ, Fleming JO, Spaan WJ, Wege H, et al. Identification of an immunodominant linear neutralization domain on the S2 portion of the murine coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure. J Virol. 1993;67(3):1185\u201394.","journal-title":"J Virol"},{"issue":"2\u20133","key":"7010_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1385\/IR:23:2-3:135","volume":"23","author":"JE Crowe Jr","year":"2001","unstructured":"Crowe JE Jr, Suara RO, Brock S, Kallewaard N, House F, Weitkamp JH. Genetic and structural determinants of virus neutralizing antibodies. Immunol Res. 2001;23(2\u20133):135\u201345.","journal-title":"Immunol Res"},{"key":"7010_CR13","first-page":"691","volume":"43","author":"Li Xuehan","year":"2020","unstructured":"Xuehan Li, Yunbao P, Yirong Li. Status quo and review of clinical application of antibody detection for 2019\u2043nCoV. Zhong Hua Jian Yan Yi Xue Za Zhi. 2020;43:691\u20136.","journal-title":"Zhong Hua Jian Yan Yi Xue Za Zhi"},{"issue":"7","key":"7010_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41423-020-0474-z","volume":"17","author":"H Ma","year":"2020","unstructured":"Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17(7):773\u20135.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"7010_CR15","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/j.jinf.2020.03.052","volume":"81","author":"Z Zeng","year":"2020","unstructured":"Zeng Z, Chen L, Pan Y, Deng Q, Ye G, Li Y, et al. Re: profile of specific antibodies to SARS-CoV-2: the first report. J Infect. 2020;81(1):e80\u20131.","journal-title":"J Infect"},{"issue":"6\u20137","key":"7010_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/00365540902919384","volume":"41","author":"Z Yang","year":"2009","unstructured":"Yang Z, Wang S, Li Q, Li Y, Wei M, Gao H, et al. Determining SARS sub-clinical infection: a longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital. Scand J Infect Dis. 2009;41(6\u20137):507\u201310.","journal-title":"Scand J Infect Dis"},{"key":"7010_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.virusres.2014.03.018","volume":"194","author":"B Meyer","year":"2014","unstructured":"Meyer B, Drosten C, Muller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014;194:175\u201383.","journal-title":"Virus Res"},{"key":"7010_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.052","author":"Z Zeng","year":"2020","unstructured":"Zeng Z, Chen L, Pan Y, Deng Q, Ye G, Li Y, et al. Re: profile of specific antibodies to SARS-CoV-2: the first report. J Infect. 2020. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.052.","journal-title":"J Infect"},{"issue":"2","key":"7010_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0016-5085(03)00882-5","volume":"125","author":"M Kaplan","year":"2003","unstructured":"Kaplan M, Gawrieh S, Cotler SJ, Jensen DM. Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. Gastroenterology. 2003;125(2):597\u2013604.","journal-title":"Gastroenterology"},{"key":"7010_CR20","doi-asserted-by":"publisher","first-page":"108409","DOI":"10.1016\/j.clim.2020.108409","volume":"2015","author":"A Gasmi","year":"2020","unstructured":"Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjorklund G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin Immunol. 2020;2015:108409.","journal-title":"Clin Immunol"},{"issue":"6","key":"7010_CR21","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S2352-3018(21)00072-2","volume":"8","author":"MA Spinelli","year":"2021","unstructured":"Spinelli MA, Lynch KL, Yun C, Glidden DV, Peluso MJ, Henrich TJ, et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. Lancet HIV. 2021;8(6):e334\u201341.","journal-title":"Lancet HIV"},{"issue":"9","key":"7010_CR22","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3201\/eid1009.040101","volume":"10","author":"PR Hsueh","year":"2004","unstructured":"Hsueh PR, Kao CL, Lee CN, Chen LK, Ho MS, Sia C, et al. SARS antibody test for serosurveillance. Emerg Infect Dis. 2004;10(9):1558\u201362.","journal-title":"Emerg Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-07010-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-07010-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-07010-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T10:10:13Z","timestamp":1641291013000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-07010-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7010"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-07010-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics committee of Zhongnan Hospital of Wuhan University approved the study (No. 2020051K). Written consent was obtained from study participants. And this study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}